- Antibodies
- New
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Tag
- Peptides
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Tag
- Biological Process >
- Proteins
- RNAi
- FL cDNA Clones
- Cell/Tissues/Lysates
Phospho-FLT3- Y589/591 AntibodyPeptide Affinity Purified Rabbit Polyclonal Antibody (Pab)
| Country | United States
Ordering Information
Australia Austria Belgium Brazil Bulgaria Canada China Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Iceland India Indonesia Ireland Israel Italy Japan Korea Latvia Lithuania Luxembourg Macedonia Malaysia Malta Netherlands Norway Pakistan Poland Portugal Romania Serbia Singapore Slovakia Slovenia Spain Sweden Switzerland Taiwan Turkey United Kingdom United States Vietnam Others 
|
|||
|---|---|---|---|---|
| Catalog # | Size | Availability | Price | |
| AP3712a | 0.1 mg 400 ul | In Stock | $ 255.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
| AP3712a-ev20 | 20 ug 100 ul | In Stock | $ 95.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
- Specification
- Citiations : 0
- Reviews
- Protocols
- Backgrounds
Phospho-FLT3- Y589/591 Antibody - Product info | |
| Application | DB
|
| Primary Accession | P36888 |
| Reactivity | Human |
| Concentration | 0.25 mg/ml |
| Isotype | Rabbit Ig |
| Calculated MW | 112903 Da |
Phospho-FLT3- Y589/591 Antibody - Additional info | |
| Gene ID 2322 | |
| Other Names FLT3; CD135; FLK2; STK1; Receptor-type tyrosine-protein kinase FLT3; FL cytokine receptor; Fetal liver kinase-2; Fms-like tyrosine kinase 3; Stem cell tyrosine kinase 1; CD_antigen=CD135; Flags: Precursor | |
| Target/Specificity This Phospho-FLT3-Y589/591 antibody is generated from rabbits immunized with a KLH conjugated synthetic phosphopeptide between 574~604 amino acids surrounding Y589/591 of human FLT3. | |
| Dilution DB~~1:500 | |
| Format Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by two-step phosphospecific peptide affinity purification. | |
| Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. | |
| Precautions Phospho-FLT3- Y589/591 Antibody is for research use only and not for use in diagnostic or therapeutic procedures. | |
Phospho-FLT3- Y589/591 Antibody - Protein Information | |
| Name FLT3 | |
| Synonyms CD135, FLK2, STK1 | |
| Function Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation of FES, FER, PTPN6/SHP, PTPN11/SHP-2, PLCG1, and STAT5A and/or STAT5B Activation of wild-type FLT3 causes only marginal activation of STAT5A or STAT5B. Mutations that cause constitutive kinase activity promote cell proliferation and resistance to apoptosis via the activation of multiple signaling pathways | |
| Cellular Location Membrane; Single-pass type I membrane protein. Endoplasmic reticulum lumen. Note=Constitutively activated mutant forms with internal tandem duplications are less efficiently transported to the cell surface and a significant proportion is retained in an immature form in the endoplasmic reticulum lumen. The activated kinase is rapidly targeted for degradation | |
| Tissue Location Detected in bone marrow, in hematopoietic stem cells, in myeloid progenitor cells and in granulocyte/macrophage progenitor cells (at protein level). Detected in bone marrow, liver, thymus, spleen and lymph node, and at low levels in kidney and pancreas. Highly expressed in T-cell leukemia | |
Phospho-FLT3- Y589/591 Antibody - Related products
AP11143a: FLT3 (Tyr589/591) Antibody
AP3712a: Phospho-FLT3- Y589/591 Antibody
AP7644a: FLT3 (CD135) Antibody (N-term)
AP7644b: FLT3 (CD135) Antibody (C-term)
BP3712a: Phospho-FLT3-Y589/591 Antibody Blocking Peptide
Phospho-FLT3- Y589/591 Antibody - Application data
-
Dot blot analysis of anti-Phospho-FLT3 (Tyr589/591) Antibody Phospho-specific Pab (Cat. #AP3712a) on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.5ug per ml.
Phospho-FLT3- Y589/591 Antibody - Research Areas
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
This gene encodes a class III receptor tyrosine kinase that regulates hematopoiesis. The receptor consists of an extracellular domain composed of five immunoglobulin-like domains, one transmembrane region, and a cytoplasmic kinase domain split into two parts by a kinase-insert domain. The receptor is activated by binding of the fms-related tyrosine kinase 3 ligand to the extracellular domain, which induces homodimer formation in the plasma membrane leading to autophosphorylation of the receptor. The activated receptor kinase subsequently phosphorylates and activates multiple cytoplasmic effector molecules in pathways involved in apoptosis, proliferation, and differentiation of hematopoietic cells in bone marrow. Mutations that result in the constitutive activation of this receptor result in acute myeloid leukemia and acute lymphoblastic leukemia.
REFERENCES
Zhonghua Xue Ye Xue Za Zhi 31(1):1-5(2010) Parcells, B.W., et al. Stem Cells 24(5):1174-1184(2006) Kiyoi, H., et al. Oncogene 21(16):2555-2563(2002)
